SCHEMBL5746016

SCHEMBL5746016

CC1C(C)N(S(=O)(=O)c2cccc(CC(=O)O)c2)CCN1c1ccc(C(F)(F)F)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 5/20 0.46
NR1H3 Q13133 5/20 0.46
POLB P06746 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
SGPL1 O95470 1/20 0.41
CHRM2 P08172 3/20 0.39
CHRM1 P11229 3/20 0.39
CHRM5 P08912 1/20 0.39
CHRM3 P20309 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA4 P22748 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
TRPV1 Q8NER1 1/20 0.39
GPR119 Q8TDV5 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5768967 0.90 PPARG (0.41) NR1H2NR1H3CYP2C9HPGDCYP2C19
SCHEMBL5778752 0.85 NR1H2 (0.40) NR1H2NR1H3HPGDGPR119
SCHEMBL1471200 0.81 NR1H2 (0.38) NR1H2NR1H3GPR119
SCHEMBL12749864 0.81 NR1H2 (0.38) NR1H2NR1H3GPR119
SCHEMBL6350344 0.81 HSD11B1 (0.45) PTGDR2
SCHEMBL5749711 0.80 HSD11B1 (0.47) NR1H2NR1H3POLBCYP2C9HPGD
SCHEMBL5748192 0.80 POLB (0.44) NR1H2NR1H3POLBCYP2C9HPGD
SCHEMBL5772309 0.80 KDM4E (0.59) CYP2C9HPGDCYP2C19CHRM2CHRM1
SCHEMBL13895262 0.78 NR1H2 (0.38) NR1H2NR1H3SGPL1GPR119
SCHEMBL12749863 0.77 GPR119 (0.41) NR1H2NR1H3GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD NR1H2 19/4885NR1H3 29/4885POLB 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.